CytoDyn Inc. CYDY

CYDY Company Overview

CytoDyn Inc. is a U.S.-based biotechnology company focused on the development of immunology and infectious disease therapeutics. The company’s primary asset is leronlimab, a monoclonal antibody targeting the CCR5 receptor, which has been investigated across multiple therapeutic areas including HIV, oncology, inflammatory diseases, and certain viral conditions. CytoDyn operates within the biotechnology and biopharmaceutical industries, with research activities centered on immune modulation and receptor-targeted therapies. The company’s revenue generation has historically been limited because its lead product candidates have not received broad commercial approval, and the company has primarily relied on capital markets financing and strategic development activities.

CytoDyn was founded in 2002 and later became publicly traded in the United States under the ticker CYDY. Over time, the company shifted its focus toward the development of leronlimab as its core platform asset. The company has positioned itself around the potential versatility of CCR5 inhibition across several disease pathways, which management has described as a differentiating strategic advantage. Public disclosures, including SEC filings, indicate that CytoDyn’s strategy has evolved from primarily HIV-related development toward a broader pipeline approach involving oncology and immune-related indications.